Daxxify is a peptide-enhanced injectable that treats frown lines. It contains peptide exchange technology to temporarily deliver the botulinum toxin to the nerve cells to improve moderate to severe lines. It works like other neuromodulators, blocking the nerve signals that cause muscle contraction and minimizing expression lines. ​ The FDA has approved Daxxify for smoothing facial wrinkles in adults. Aesthetic clinicians regard it as the first major Botox® competitor to emerge in decades. The difference with this injectable is that it keeps wrinkles away longer than its contemporaries. In clinical trials submitted to the FDA, 80% of Daxxify patients had little to no visible facial wrinkling after four months. About half had little evidence of lines and wrinkles six months after injections.